Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Gastrointestinal Cancer Market Growth From $30.33 Billion In 2026 To $47.4 Billion By 2030 At A CAGR Of 11.8%
The gastrointestinal cancer market has experienced significant expansion in recent years. This market is projected to grow from $27.05 billion in 2025 to $30.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. The growth observed in the past can be attributed to the increasing prevalence of gastrointestinal cancers, improvements in diagnostic imaging capabilities, enhanced awareness regarding early cancer detection, advancements in oncology drug development, and better access to cancer treatment facilities.
The gastrointestinal cancer market is projected to experience swift expansion in the coming years. It is anticipated to reach $47.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. This anticipated growth throughout the forecast period stems from factors such as heightened investments in personalized oncology, the growing acceptance of biomarker-based diagnostics, the broadening of immuno-oncology pipelines, the expanding application of minimally invasive diagnostics, and increased healthcare spending dedicated to cancer treatment. Key trends expected during this period involve the greater uptake of targeted GI cancer therapies, the increased utilization of molecular diagnostics, a stronger emphasis on immunotherapy combinations, the enlargement of early cancer screening initiatives, and improved integration of precision medicine.
Get A Free Sample Report With In-Depth Market Insights:
Gastrointestinal Cancer Market Growth Factors Behind Sustained Expansion
The increasing embrace of targeted therapies is anticipated to stimulate the expansion of the gastrointestinal cancer market in the coming years. These treatments function by precisely blocking the proliferation of cancer cells through interaction with specific molecular targets, thereby minimizing harm to healthy, normal cells. Targeted therapies are specifically engineered to engage with particular molecular pathways or genetic mutations that drive a disease, especially within the context of cancer. Unlike conventional treatments such as chemotherapy, which attack both healthy and diseased cells indiscriminately, targeted therapies concentrate on the unique characteristics of an individual patient’s condition. For gastrointestinal (GI) cancer, targeted therapies act on specific genes or proteins that control tumor growth, facilitating precise and effective treatment. This leads to improved outcomes with fewer adverse effects compared to traditional chemotherapy. As an illustration, in July 2023, reports from the US-based professional membership organization American Society of Gene & Cell Therapy (ASGCT) and the US-based provider of drugs and devices Citeline indicated that at the conclusion of quarter one (Q1) 2023, there were 247 gene therapies in Phase II; this number saw a 5% increase, reaching 260 by the end of quarter two (Q2). Therefore, the growing adoption of targeted therapies is propelling the growth of the gastrointestinal cancer market.
Gastrointestinal Cancer Market Segmentation: How Does The Market Break Down By Category?
The gastrointestinal cancer market covered in this report is segmented –
1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types
2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics
3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer
2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors
3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors
4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors
5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer
6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor
Gastrointestinal Cancer Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies within the gastrointestinal cancer market are concentrating on developing advanced solutions, such as monoclonal antibody treatments, with the aim of enhancing patient survival rates and minimizing adverse effects associated with therapy. Monoclonal antibody treatment involves the utilization of laboratory-created antibodies that precisely identify and attach to cancer cells, thereby assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, introduced VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, having secured approval from the European Commission. This serves as a first-line treatment for adults diagnosed with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval establishes VYLOY as the initial and exclusive therapy in the European Union designed to target CLDN18.2, a biomarker present in approximately 38% of these patients, a conclusion drawn from positive clinical trial data from the SPOTLIGHT and GLOW studies.
Gastrointestinal Cancer Market Competitive Overview And Top Companies
Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd
View The Full Gastrointestinal Cancer Market Report:
Gastrointestinal Cancer Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model








